HGEN

Lenzilumab

Relapsed or Refractory Diffuse Large B-Cell Lymphoma / RR DLBCL

Stage (next event)

Expected Date

Phase 1b (Results)

Q4 2020

Catalyst Info & Data Links

TITLE: Lenzilumab for Relapsed or Refractory Large B-Cell Lymphoma - Phase 1b Results

  • ClinicalTrial.gov (NCT04314843): Study of Lenzilumab and Axicabtagene Ciloleucel in Participants With Relapsed or Refractory Large B-Cell Lymphoma (ZUMA-19)


WHAT IS THE NEXT CATALYST EVENT?

  • 1. Phase Ib results

  • 2. Phase II interim analysis

  • 3. Six-month efficacy data

  • See slide 8 of the corporate slide deck at this LINK


WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?

  • 1. December 2020 (Q4 2020)

  • 2. H1 2021

  • 3. H2 2021


PRIOR DATA

PRESS RELEASES

Mechanism of Action

MECHANISM OF ACTION / RATIONALE

  • Lenzilumab is a proprietary Humaneered® (“Humaneered”) anti-human granulocyte-macrophage colony-stimulating factor (“GM-CSF”) monoclonal antibody. Lenzilumab is a monoclonal antibody that has been proven in animal models to neutralize GM-CSF, a cytokine that we believe is of critical importance in the hyperinflammatory cascade, sometimes referred to as cytokine release syndrome (“CRS”) or cytokine storm, associated with COVID-19, chimeric antigen receptor T-cell (“CAR-T”) therapy and acute Graft versus Host Disease (“GvHD”) associated with bone marrow transplants. Lenzilumab binds to and neutralizes GM-CSF.

Updated by HC

Prior Data (click to view full image)

Chart

Trial Design / Revenue (click to view full image)

Chart

Recent Posts

See what the community is saying - click to see full post

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon